Skip to main content

Table 3 Principal Component analysis (PCA); the association between tumor characteristics and lipoprotein subfractions by NMR

From: Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer

  Univariable Multivariable
Tumor characteristics β-coefficient 95 % CI p-value β-coefficient 95 % CI p-value
Progesterone receptor (%)
 Total plasma Apolipoprotein A1, mg/dL 0.41 (0.17, 0.65) 0.001 0.46 (0.22, 0.69) <0.001
 HDL Cholesterol, mg/dL 0.86 (0.41, 1.31) <0.001 0.95 (0.51, 1.39) <0.001
 HDL Free Cholesterol, mg/dL 2.64 (1.03, 4.26) 0.002 2.88 (1.28, 4.48) 0.001
 HDL Phospholipids, mg/dL 0.66 (0.31, 1.01) <0.001 0.70 (0.36, 1.04) <0.001
 HDL Apolipoprotein A1, mg/dL 0.50 (0.22, 0.78) 0.001 0.56 (0.29, 0.83) <0.001
 HDL Apolipoprotein A2, mg/dL 1.16 (0.06, 2.26) 0.040 1.53 (0.48, 2.58) 0.005
 HDL1 Phospholipids, mg/dL 1.02 (0.39, 1.64) 0.002 0.96 (0.35, 1.57) 0.003
 HDL1Cholesterol, mg/dL 1.20 (0.43, 1.97) 0.003 1.15 (0.41, 1.89) 0.003
 HDL1Free Cholesterol, mg/dL 3.36 (0.80, 5.92) 0.011 3.44 (0.95, 5.93) 0.008
 HDL1 Apolipoprotein A1, mg/dL 0.81 (0.29, 1.34) 0.003 0.76 (0.25, 1.27) 0.004
 HDL1 Apolipoprotein A2, mg/dL 6.75 (2.20, 11.3) 0.004 6.39 (2.08, 10.7) 0.004
 HDL2 Phospholipids, mg/dL 2.54 (0.95, 4.13) 0.002 2.30 (0.61, 3.98) 0.008
 HDL2 Cholesterol, mg/dL 3.87 (1.19, 6.54) 0.005 4.42 (1.70, 7.15) 0.002
 HDL2 Free Cholesterol, mg/dL 10.9 (3.48, 18.4) 0.005 11.6 (4.39, 18.9) 0.002
 HDL2 Apolipoprotein A2, mg/dL 6.01 (0.26, 11.8) 0.041 6.74 (1.26, 12.2) 0.017
 HDL2 Apolipoprotein A1, mg/dL 2.15 (0.79, 3.51) 0.003 2.29 (0.95, 3.63) 0.001
 HDL3 Phospholipids, mg/dL 2.53 (0.95, 4.11) 0.002 2.88 (1.32, 4.43) 0.001
 HDL3 Cholesterol, mg/dL 3.75 (1.28, 6.22) 0.004 4.44 (1.94, 6.95) 0.001
 HDL3 Free Cholesterol, mg/dL 11.48 (3.06, 19.9) 0.008 13.5 (5.05, 22.0) 0.002
 HDL3 Apolipoprotein A1, mg/dL 2.04 (0.73, 3.34) 0.003 2.38 (1.09, 3.66) 0.001
 VLDL4 Cholesterol, mg/dL −3.59 (−6.88,−0.31) 0.033 −3.76 (−7.16,−0.37) 0.031
 VLDL 4 Free Cholesterol, mg/dL −7.59 (−14.9, −0.27) 0.043 −7.75 (−15.3,−0.20) 0.044
Ki 67, %
 HDL Phospholipids, mg/dL −0.25 (−0.47, −0.02) 0.033 −0.31 (−0.53,−0.08) 0.008
 HDL1 Cholesterol, mg/dL −0.48 (−0.96, −0.01) 0.048 −0.54 (−1.00,−0.07) 0.024
 HDL1 Phospholipids, mg/dL −0.40 (−0.80,−0.01) 0.043 −0.46 (−0.84,−0.08) 0.020
 HDL1 Apolipoprotein A1, mg/dL −0.31 (−0.64, 0.02) 0.066 −0.35 (−0.67,−0.03) 0.032
 HDL1 Apolipoprotein A2, mg/dL −3.23 (−6.01,−0.45) 0.024 −3.28 (−5.94,−0.62) 0.017
 HDL2 Phospholipids, mg/dL −1.08 (−2.06,−0.09) 0.033 −1.30 (−2.28,−0.31) 0.011
Nodal metastasis
 VLDL1 Triglycerides, mg/dL 0.03 (0.00, 0.06) 0.033 0.03 (0.00, 0.07) 0.036
 VLDL1 Free Cholesterol, mg/dL 0.38 (0.01, 0.74) 0.045 0.41 (−0.01, 0.83) 0.057
 LDL2 Free Cholesterol, mg/dL −0.19 (−0.38,−0.00) 0.049 −0.17 (−0.37, 0.02) 0.084
 LDL3 Free Cholesterol, mg/dL −0.21 (−0.40,−0.03) 0.026 −0.20 (−0.40,−0.01) 0.049
Estrogen receptor (%) No significant associations
Grade 1–3
Tumor size, mm
  1. Univariable and multivariable linear regression model. Multivariable model adjusted for age, BMI and menopausal status. 95 % Confidence Interval. Significance level p < 0.05
  2. Abbreviations: HDL high-density lipoprotein, VLDL very-low-density lipoprotein, LDL low-density lipoprotein